Does the media refer more to NAMS or ETON?

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 3 mentions for NewAmsterdam Pharma and 2 mentions for Eton Pharmaceuticals. NewAmsterdam Pharma's average media sentiment score of 1.29 beat Eton Pharmaceuticals' score of 0.94 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ETON or DNLI?

In the previous week, Denali Therapeutics had 3 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 5 mentions for Denali Therapeutics and 2 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.94 beat Denali Therapeutics' score of 0.75 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ETON or TLX?

Eton Pharmaceuticals has higher earnings, but lower revenue than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eton Pharmaceuticals $79.95M 12.54 -$4.60M -$0.07 N/A Telix Pharmaceuticals $803.79M 4.70 -$7.12M N/A N/A

Does the media favor ETON or TLX?

In the previous week, Telix Pharmaceuticals had 5 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 7 mentions for Telix Pharmaceuticals and 2 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.94 beat Telix Pharmaceuticals' score of 0.29 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CPRX or ETON?

In the previous week, Catalyst Pharmaceuticals had 2 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 4 mentions for Catalyst Pharmaceuticals and 2 mentions for Eton Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.12 beat Eton Pharmaceuticals' score of 0.94 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eton Pharmaceuticals (ETON) Competitors

$36.61 -0.72 (-1.93%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$36.67 +0.06 (+0.18%)

As of 07/10/2026 07:26 PM Eastern

Compare

ETON vs. NAMS, DNLI, TLX, GPCR, and CPRX

Should you buy Eton Pharmaceuticals stock or one of its competitors? MarketBeat compares Eton Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eton Pharmaceuticals include NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), Telix Pharmaceuticals (TLX), Structure Therapeutics (GPCR), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry.

How does Eton Pharmaceuticals compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Eton Pharmaceuticals (NASDAQ:ETON) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NewAmsterdam Pharma currently has a consensus price target of $49.00, suggesting a potential upside of 38.97%. Eton Pharmaceuticals has a consensus price target of $41.00, suggesting a potential upside of 11.99%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe NewAmsterdam Pharma is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Eton Pharmaceuticals has higher revenue and earnings than NewAmsterdam Pharma. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	183.20	-$203.82M	-$1.79	N/A
Eton Pharmaceuticals	$79.95M	12.54	-$4.60M	-$0.07	N/A

NewAmsterdam Pharma has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

Eton Pharmaceuticals has a net margin of -1.70% compared to NewAmsterdam Pharma's net margin of -943.23%. Eton Pharmaceuticals' return on equity of -5.68% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 3 mentions for NewAmsterdam Pharma and 2 mentions for Eton Pharmaceuticals. NewAmsterdam Pharma's average media sentiment score of 1.29 beat Eton Pharmaceuticals' score of 0.94 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eton Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NewAmsterdam Pharma beats Eton Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Denali Therapeutics?

Eton Pharmaceuticals (NASDAQ:ETON) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Eton Pharmaceuticals presently has a consensus target price of $41.00, suggesting a potential upside of 11.99%. Denali Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 33.37%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81

Eton Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

In the previous week, Denali Therapeutics had 3 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 5 mentions for Denali Therapeutics and 2 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.94 beat Denali Therapeutics' score of 0.75 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Denali Therapeutics	N/A	-52.20%	-43.86%

Eton Pharmaceuticals has higher earnings, but lower revenue than Denali Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	12.54	-$4.60M	-$0.07	N/A
Denali Therapeutics	$330.53M	12.33	-$512.54M	-$2.88	N/A

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Denali Therapeutics beats Eton Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Telix Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Telix Pharmaceuticals has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Telix Pharmaceuticals' return on equity of 0.00% beat Eton Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Telix Pharmaceuticals	N/A	N/A	N/A

Eton Pharmaceuticals currently has a consensus target price of $41.00, indicating a potential upside of 11.99%. Telix Pharmaceuticals has a consensus target price of $21.00, indicating a potential upside of 88.51%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Eton Pharmaceuticals has higher earnings, but lower revenue than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	12.54	-$4.60M	-$0.07	N/A
Telix Pharmaceuticals	$803.79M	4.70	-$7.12M	N/A	N/A

Eton Pharmaceuticals has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market.

In the previous week, Telix Pharmaceuticals had 5 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 7 mentions for Telix Pharmaceuticals and 2 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.94 beat Telix Pharmaceuticals' score of 0.29 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Telix Pharmaceuticals beats Eton Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Structure Therapeutics?

Eton Pharmaceuticals (NASDAQ:ETON) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Eton Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.5, suggesting that its stock price is 250% less volatile than the broader market.

Eton Pharmaceuticals has higher revenue and earnings than Structure Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Structure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	12.54	-$4.60M	-$0.07	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Structure Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Structure Therapeutics	N/A	-24.91%	-23.67%

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Eton Pharmaceuticals presently has a consensus target price of $41.00, suggesting a potential upside of 11.99%. Structure Therapeutics has a consensus target price of $110.55, suggesting a potential upside of 107.17%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

In the previous week, Eton Pharmaceuticals had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 2 mentions for Eton Pharmaceuticals and 1 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.87 beat Eton Pharmaceuticals' score of 0.94 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eton Pharmaceuticals	Positive
Structure Therapeutics	Very Positive

Summary

Eton Pharmaceuticals and Structure Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Eton Pharmaceuticals (NASDAQ:ETON) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Eton Pharmaceuticals' net margin of -1.70%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Eton Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

Catalyst Pharmaceuticals has higher revenue and earnings than Eton Pharmaceuticals. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$596.96M	6.45	$214.33M	$1.74	18.09
Eton Pharmaceuticals	$79.95M	12.54	-$4.60M	-$0.07	N/A

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Catalyst Pharmaceuticals presently has a consensus price target of $32.00, suggesting a potential upside of 1.68%. Eton Pharmaceuticals has a consensus price target of $41.00, suggesting a potential upside of 11.99%. Given Eton Pharmaceuticals' higher probable upside, analysts clearly believe Eton Pharmaceuticals is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Catalyst Pharmaceuticals had 2 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 4 mentions for Catalyst Pharmaceuticals and 2 mentions for Eton Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.12 beat Eton Pharmaceuticals' score of 0.94 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eton Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Catalyst Pharmaceuticals beats Eton Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

Get Eton Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ETON vs. The Competition

Export

Metric	Eton Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.02B	$3.76B	$7.14B	$12.64B
Dividend Yield	N/A	2.17%	2.68%	7.83%
P/E Ratio	-522.93	21.83	27.42	24.58
Price / Sales	12.54	323.85	593.42	121.59
Price / Cash	7,202.12	147.64	49.34	60.04
Price / Book	37.36	8.41	10.88	6.38
Net Income	-$4.60M	$23.85M	$3.59B	$331.87M
7 Day Performance	-2.37%	-0.75%	-0.26%	0.37%
1 Month Performance	14.01%	8.81%	4.52%	0.53%
1 Year Performance	152.66%	53.66%	29.17%	21.96%

Eton Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ETON Eton Pharmaceuticals	2.9677 of 5 stars	$36.61 -1.9%	$41.00 +12.0%	+135.3%	$1.02B	$79.95M	N/A	20
NAMS NewAmsterdam Pharma	3.4614 of 5 stars	$35.30 +1.1%	$49.00 +38.8%	+60.1%	$4.13B	$22.57M	N/A	4	News Coverage Positive News Options Volume
DNLI Denali Therapeutics	3.4284 of 5 stars	$25.59 -0.6%	$34.25 +33.8%	+67.3%	$4.04B	$330.53M	N/A	430	News Coverage
TLX Telix Pharmaceuticals	4.5629 of 5 stars	$11.73 -3.5%	$21.13 +80.1%	-30.8%	$3.98B	$803.79M	N/A	1,184	Analyst Forecast Gap Up
GPCR Structure Therapeutics	2.7759 of 5 stars	$54.65 -0.2%	$110.55 +102.3%	+182.3%	$3.87B	N/A	N/A	136	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ETON) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eton Pharmaceuticals (ETON) Competitors

ETON vs. NAMS, DNLI, TLX, GPCR, and CPRX

How does Eton Pharmaceuticals compare to NewAmsterdam Pharma?

Summary

How does Eton Pharmaceuticals compare to Denali Therapeutics?

Summary

How does Eton Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

How does Eton Pharmaceuticals compare to Structure Therapeutics?

Summary

How does Eton Pharmaceuticals compare to Catalyst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eton Pharmaceuticals (ETON) Competitors

ETON vs. NAMS, DNLI, TLX, GPCR, and CPRX

How does Eton Pharmaceuticals compare to NewAmsterdam Pharma?

Do insiders & institutionals hold more shares of NAMS or ETON?

Do analysts recommend NAMS or ETON?

Which has higher valuation and earnings, NAMS or ETON?

Which has more volatility and risk, NAMS or ETON?

Is NAMS or ETON more profitable?

Does the media refer more to NAMS or ETON?

Summary

How does Eton Pharmaceuticals compare to Denali Therapeutics?

Do analysts recommend ETON or DNLI?

Which has more risk and volatility, ETON or DNLI?

Does the media favor ETON or DNLI?

Is ETON or DNLI more profitable?

Which has preferable earnings & valuation, ETON or DNLI?

Do institutionals & insiders hold more shares of ETON or DNLI?

Summary

How does Eton Pharmaceuticals compare to Telix Pharmaceuticals?

Is ETON or TLX more profitable?

Do analysts rate ETON or TLX?

Do institutionals and insiders believe in ETON or TLX?

Which has higher earnings & valuation, ETON or TLX?

Which has more volatility & risk, ETON or TLX?

Does the media favor ETON or TLX?

Summary

How does Eton Pharmaceuticals compare to Structure Therapeutics?

Which has more risk & volatility, ETON or GPCR?

Which has higher earnings and valuation, ETON or GPCR?

Is ETON or GPCR more profitable?

Do insiders & institutionals hold more shares of ETON or GPCR?

Do analysts rate ETON or GPCR?

Does the media prefer ETON or GPCR?

Summary

How does Eton Pharmaceuticals compare to Catalyst Pharmaceuticals?

Is CPRX or ETON more profitable?

Which has stronger valuation and earnings, CPRX or ETON?

Do institutionals & insiders have more ownership in CPRX or ETON?

Which has more risk & volatility, CPRX or ETON?

Do analysts rate CPRX or ETON?

Does the media refer more to CPRX or ETON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools